BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8162331)

  • 1. TP53 tumor-suppressor gene and human carcinogenesis.
    Basset-Séguin N; Molès JP; Mils V; Dereure O; Guilhou JJ
    Exp Dermatol; 1993 Jun; 2(3):99-105. PubMed ID: 8162331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 tumor suppressor gene and skin carcinogenesis.
    Basset-Séguin N; Molès JP; Mils V; Dereure O; Guilhou JJ
    J Invest Dermatol; 1994 Nov; 103(5 Suppl):102S-106S. PubMed ID: 7963669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
    Stein T; Crighton D; Boyle JM; Varley JM; White RJ
    Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing TP53 status in human tumours to evaluate clinical outcome.
    Soussi T; Béroud C
    Nat Rev Cancer; 2001 Dec; 1(3):233-40. PubMed ID: 11902578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy.
    Wang XW; Harris CC
    Cancer Surv; 1996; 28():169-96. PubMed ID: 8977035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
    Lang GA; Iwakuma T; Suh YA; Liu G; Rao VA; Parant JM; Valentin-Vega YA; Terzian T; Caldwell LC; Strong LC; El-Naggar AK; Lozano G
    Cell; 2004 Dec; 119(6):861-72. PubMed ID: 15607981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 from basic research to clinical applications.
    Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
    Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family.
    Güran S; Tunca Y; Imirzalioğlu N
    Cancer Genet Cytogenet; 1999 Sep; 113(2):145-51. PubMed ID: 10484981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
    Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
    Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
    Evans SC; Lozano G
    Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and disease: when the guardian angel fails.
    Royds JA; Iacopetta B
    Cell Death Differ; 2006 Jun; 13(6):1017-26. PubMed ID: 16557268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
    Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
    Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies.
    Schlegelberger B; Kreipe H; Lehmann U; Steinemann D; Ripperger T; Göhring G; Thomay K; Rump A; Di Donato N; Suttorp M
    Pediatr Blood Cancer; 2015 Aug; 62(8):1481-4. PubMed ID: 25787918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
    Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
    Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
    Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
    Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.